Group 1 - The stock price of Chengda Pharmaceutical closed at 27.34 yuan on August 14, 2025, down by 1.59 yuan, representing a decline of 5.50% from the previous trading day [1] - The trading volume on that day was 98,100 hands, with a transaction amount of 276 million yuan, and a turnover rate of 9.04% [1] - Chengda Pharmaceutical's main business includes pharmaceutical research and development, production, and involves areas such as CRO and biopharmaceuticals [1] Group 2 - The company is progressing with its innovative biocell drug project, although specific advancements or clinical trial arrangements have not been disclosed [1] - On August 14, there was a net outflow of 18.51 million yuan in main funds, with a cumulative net outflow of 14.57 million yuan over the past five days [1]

诚达药业首次公开发行股票的发行费用总额为13,576.31万元，其中，保荐承销费用11,792.90万元。 2023年7月3日，诚达药业发布2022年度权益分派实施公告。公司2022年年度权益分派方案为：以公司现 有总股本96,696,140股为基数，向全体股东每10股派3.000000元人民币现金，同时，以资本公积金向全 体股东每10股转增6.000000股。本次权益分派股权登记日为2023年7月6日，除权除息日为2023年7月7 日。 诚达药业首次公开发行股票募集资金总额为175,721.06万元，扣除发行费用后募集资金净额162,144.75万 元。诚达药业实际募资净额比原拟募集资金多110,816.71万元。诚达药业于2022年1月14日披露的招股说 明书显示，该公司原拟募集资金51,328.04万元，分别用于"医药中间体项目、原料药项目及研发中心扩 建项目"和"补充流动资金"。 中国经济网北京8月14日讯诚达药业（301201）(301201.SZ)今日股价下跌，截至收盘报27.34元，跌幅 5.50%，该股目前处于破发状态。 诚达药业于2022年1月20日在深交所创业板上市，公开发行新股2,417 ...

Market Overview - On August 14, the medical services sector declined by 0.47%, with XD Zhaoyan leading the drop [1] - The Shanghai Composite Index closed at 3666.44, down 0.46%, while the Shenzhen Component Index closed at 11451.43, down 0.87% [1] Top Gainers in Medical Services - Nanjing Momo Biological Technology (688265) saw a closing price of 60.60, up 16.20% with a trading volume of 45,800 shares and a transaction value of 262 million [1] - Innovation Medical (002173) closed at 24.92, up 10.02% with a trading volume of 1,071,000 shares and a transaction value of 2.609 billion [1] - Sanbo Brain Science (301293) closed at 67.82, up 8.51% with a trading volume of 396,800 shares and a transaction value of 2.618 billion [1] Top Losers in Medical Services - XD Zhaoyan (603127) closed at 32.21, down 5.74% with a trading volume of 455,800 shares and a transaction value of 1.497 billion [2] - Chengda Pharmaceutical (301201) closed at 27.34, down 5.50% with a trading volume of 98,100 shares and a transaction value of 276 million [2] - ST Biological (000504) closed at 10.75, down 5.04% with a trading volume of 110,000 shares and a transaction value of 120 million [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 364 million from institutional investors, while retail investors saw a net inflow of 138 million [2] - Notable net inflows from retail investors were observed in Innovation Medical (002173) with 117 million, while significant outflows were noted in Sanbo Brain Science (301293) with 46 million [3]

Market Overview - The medical services sector increased by 1.71% on August 11, with Haitai Biological leading the gains [1] - The Shanghai Composite Index closed at 3647.55, up 0.34%, while the Shenzhen Component Index closed at 11291.43, up 1.46% [1] Top Performers - Haitai Biological (300683) closed at 55.27, up 8.67% with a trading volume of 131,700 shares and a transaction value of 708 million [1] - Sunshine Nuohua (688621) closed at 68.66, up 8.47% with a trading volume of 88,200 shares and a transaction value of 581 million [1] - Chengda Pharmaceutical (301201) closed at 29.56, up 7.57% with a trading volume of 101,900 shares and a transaction value of 294 million [1] Other Notable Stocks - Innovative Medical (002173) closed at 18.72, up 6.36% with a trading volume of 1,476,200 shares and a transaction value of 2.739 billion [1] - ST Biological (000504) closed at 12.54, up 5.03% with a trading volume of 85,600 shares and a transaction value of 10.7 million [1] Fund Flow Analysis - The medical services sector saw a net inflow of 782 million from institutional investors, while retail investors experienced a net outflow of 751 million [2] - The sector's overall fund flow indicates a strong interest from institutional investors despite retail selling pressure [2] Individual Stock Fund Flow - WuXi AppTec (603259) had a net inflow of 296 million from institutional investors, while retail investors saw a net outflow of 282 million [3] - Kanglong Chemical (300759) experienced a net inflow of 181 million from institutional investors, with retail investors also showing a net outflow of 208 million [3] - Innovative Medical (002173) had a net inflow of 163 million from institutional investors, but retail investors faced a significant net outflow of 44.93 million [3]

证券之星消息，8月4日医疗服务板块较上一交易日下跌0.26%，昭衍新药领跌。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | --- | --- | --- | --- | --- | --- | --- | | 688265 | 南模生物 | 43.73 | 20.01% | | 4.08万 | 1.66亿 | | 688621 | 阳光诺和 | 66.54 | 14.84% | | 12.60万 | 8.15亿 | | 301201 | 诚达药业 | 28.10 | 4.04% | | 10.58万 | 2.93亿 | | 688222 | 成都先导 | 24.74 | 3.82% | | 33.55万 | 7.91亿 | | 002172 | 澳洋健康 | 4.25 | 3.41% | | 70.07万 | 2.93亿 | | 688046 | 药康生物 | 16.41 | 3.01% | | 4.55万 | 7293.23万 | | ...

Core Viewpoint - The healthcare services sector experienced a 1.3% increase in value with a net capital inflow of 619 million, indicating positive market sentiment towards the industry [1] Sector Performance - The healthcare services sector saw 31 stocks rise while 13 stocks declined on the reporting day [1] - The top ten decliners in the sector included Chengda Pharmaceutical (-13.12%), Chengdu Xian Dao (-2.8%), Huakang Clean (-2.62%), and others, reflecting a mixed performance within the industry [1] Notable Stocks - Key stocks with significant movements included: - Maipu Medical: Current price 68.25, up 10.58%, with a net capital inflow of 1.77 million [1] - Medicy: Current price 64.59, up 8.83%, with a net capital inflow of 2.49 million [1] - He Yuan Biological: Current price 8.07, up 8.61%, with a net capital inflow of 4.05 million [1] - Other notable stocks included Zhaoyan New Drug, Kailai Ying, and Kanglong Chemical, each showing varying degrees of price increases and capital inflows [1]

Group 1 - The stock price of Chengda Pharmaceutical (301201.SZ) fell by 13.12% to 27.62 yuan as of the close on July 23, 2023 [1] - Chengda Pharmaceutical was listed on the Shenzhen Stock Exchange's ChiNext board on January 20, 2022, with an initial public offering (IPO) of 24,174,035 shares at a price of 72.69 yuan per share [1] - The highest stock price recorded on the first day of trading was 188.00 yuan, indicating a significant decline since then, as the stock is currently in a state of "breaking" [1] Group 2 - The total amount raised from the IPO was 1,757.21 million yuan, with a net amount of 1,621.45 million yuan after deducting issuance costs [1] - The actual net fundraising exceeded the original planned amount by 1,108.17 million yuan, which was initially set at 513.28 million yuan for various projects and working capital [1] - The total issuance costs for the IPO were 135.76 million yuan, with underwriting fees amounting to 117.93 million yuan [1] Group 3 - On July 3, 2023, Chengda Pharmaceutical announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve conversion of 6 additional shares for every 10 shares held [2] - The record date for the equity distribution was set for July 6, 2023, and the ex-dividend date was July 7, 2023 [2]

Group 1 - The innovative drug sector is experiencing a resurgence, with significant stock price increases for companies such as Chengda Pharmaceutical (+14.05%) and Huisheng Pharmaceutical (+9.45%) [1][2] - The National Healthcare Security Administration (NHSA) is actively promoting high-quality development of innovative drugs through a series of meetings and discussions with industry representatives [3] - The NHSA's commitment to supporting genuine innovation and establishing a comprehensive value evaluation system for innovative drugs is expected to enhance the efficient use of healthcare resources [3] Group 2 - CITIC Securities reports that the NHSA's ongoing efforts in centralized procurement and negotiation will shift the market focus from low-price competition to quality and cost control, benefiting companies with strong quality systems and cost advantages [4] - The innovative drug sector is anticipated to receive continued policy support, with commercial insurance policies providing additional growth opportunities [4] - By 2025, the domestic innovative drug industry is expected to reach a turning point, transitioning from capital-driven to profit-driven growth, presenting dual opportunities for performance and valuation recovery [4]

Core Viewpoint - The innovative drug concept stocks have shown significant activity, with Chengdu Xian Dao and Chengda Pharmaceutical both rising over 10% following a meeting by the National Medical Insurance Administration regarding the evaluation of innovative drugs and medical devices [1] Group 1: Stock Performance - Chengdu Xian Dao and Chengda Pharmaceutical both experienced stock increases exceeding 10% [1] - Other companies such as Bai Ao Tai, Sai Sheng Pharmaceutical, Li Zhu Group, Hai Te Biological, Chen Xin Pharmaceutical, and Jian Kang Yuan saw stock rises of over 5% [1] Group 2: Regulatory Developments - The National Medical Insurance Administration held the first session of a series of discussions focused on supporting innovative drugs and medical devices [1] - The discussions centered on the topic of conducting comprehensive value assessments for innovative drugs and medical devices [1]

Group 1 - The CRO concept sector experienced a short-term surge, with Chengda Pharmaceutical (301201) rising over 10% [1] - Other companies such as Xuantai Pharmaceutical, Medisi, Saintno Biological, Sichuan Shuangma (000935), and Dezhan Health (000813) also saw increases [1] - There is a notable flow of "smart money" into the market, indicating a strategic investment trend [1]